Autoaggression and tumor rejection: It takes more than self-specific T-cell activation

Immunological Reviews

Volumn 169, Issue , 1999, Pages 263-272

  Ganss, Ruth ^d   Limmer, Andreas ^b   Sacher, Torsten ^a   Arnold, Bernd ^a   Hämmerling, Günter J ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Tumor Immunology Program   (Germany)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL MODEL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; EFFECTOR CELL; EXTRAVASATION; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PANCREAS ISLET CELL CARCINOMA; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TARGET ORGAN; TRANSGENIC MOUSE; TUMOR REJECTION;

ADENOMA, ISLET CELL; ANIMALS; AUTOIMMUNITY; CYTOKINES; DISEASE MODELS, ANIMAL; GRAFT REJECTION; HUMANS; IMMUNOTHERAPY; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; SELF TOLERANCE; T-LYMPHOCYTES;

EID: 0032775746     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01321.x     Document Type: Review

References (62)

1. 1. Wucherpfennig KW, et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 1994;152:5581-5592.
2. 2. Ohashi PS. et al. Ablation of tolerance and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65:305-317.
3. 3. Schönrich G, et al. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 1991;65:293-304.
4. + T cells. Eur J Immunol 1992;22:1013-1022.
5. 5. Hadden JW. The immunopharmacology of head and neck cancer: an update. Int J Immunopharmacol 1998;19:629-644.
6. 6. Wick M, et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 1997:186:229-238.
7. 7. Speiser DE, et al. Tumor antigens of peripheral solid tumors do not activate naive or primed T cells: implications for immunotherapy and autoimmune disease. J Exp Med 1997;186:645-653.
8. 8. Prévost-Blondel A, Zimmerann C, Stemmer C, Kulmburg P, Rosentlial FM, Pircher H. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol 1998:161:2187-2194.
9. 9. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kündig T, Hengartner H. Antigen localisation regulates immune responses in a dose-and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997;156:199 209.
10. 10. Oldstone MBA, Nerenberg M, Southern P, Price J, Lewicki H. Virus infection triggers insulin -dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991:65, 319-331.
11. 11. Staveley-O'Carroll K, et al. Induction of antigen specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998;95:1178-1183.
12. 12. Von Herrath MG, Guerder S, Lewicki H, Flavell RA, Oldstone MBA. Coexpression of B7-1 and viral ("self") transgenes in pancreatic β cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes. Immunity 1995;3:727-738.
13. 13, Guerder S, Picarella DE, Linsley PS, Flavell RA. Costimulator B7-1 confers antigen-presenting cell function to parenchymal tissue and in conjunction with tumor necrosis factor α leads to autoimmunity in transgenic mice. Proc Natl Acad Sci USA 1994;91:5138-5142.
14. 14. Guerder S, Meyerhoff J, Flavell R. The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity 1994;I:155-166.
15. 15. Chen L, et al. Tumor immunogenicity determines the effect of B7 costimulalion on T cell-mediated tumor immunity. J Exp Med 1994;179:523-532.
16. 16. Möller P, Hämmerling GJ. The role of surface HLA-A, B, C molecules in tumour immunity. Cancer Surv 1992;13:101-127.
17. 17. Pardoll DM. Cancer vaccines. Nat Med 1998;4 (Suppl):525-531.
18. 18. Carbone FR, Kurts C, Bennett SRM, Miller JFAP, Healh WR. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol Today 1998;19:368-373.
19. 19. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class 1-restricted tumor antigens. Science 1994;264:961-965.
20. 20. Kurts C, Miller JFAP, Subramaniam RM, Carbone FR, Heath WR. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 1998;188:409-414.
21. + T cell deletion induced by cross-presentation of self antigens and favors autoimmunity. J Exp Med 1997;186:2057-2062.
22. 22. Webb S, Morris C, Sprent J, Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 1990;63:1249-1256.
23. + T cells specific for a pancreatic β cell neo-antigen. Immunity 1995;2:573-585.
24. + T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). J Exp Med 1998;188:415-420.
25. 25. Van Parijs L, Peterson DA, Abbas AK. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigen. Immunity 1998;8:265-274.
26. 26. Hahne M, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-1366.
27. 27. Walker PR, Saas P, Dietrich P-Y. Tumor expression of Fas ligand (CD95L) and the consequences. Curr Opin Immunol 1998;10:564-572.
28. 28. King C, Sarvetnick N. Organ-specific autoimmunity. Curr Opin Immunol 1997;9:863-871.
29. 29. Oldstone MBA. Molecular mimicry and autoimmune disease. Cell 1987;50:819-820.
30. 30. Ufret-Vincenty R, et al. In vivo survival of viral antigen-specific T cells that induce experimental autoimmune encephalomyclitis. J Exp Med 1998:188:1725-1738.
31. 31. Horwitz MS, Bradley LM, Harhertson J, Krahl T, Lee J, Sarvetnick N. Diabetes induced by coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 1998;4:781-785.
32. 32. Segal BM, Klinman DM, Shevach EM. Microbial products induce autoimmune disease by an IL-12-dependent pathway. J Immunol 1997;158:5087-5090.
33. 33. Handel-Fernandez ME, Cheng X, Herbert LM, Lopezes. Downregulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype is responsible for impaired IFN-γ production in mammary tumor-bearing mice. J Immunol 1997;158:280-286.
34. 34. Zitvogel L, et al. Cancer immunotherapy of established tumors with IL-12. J Immunol 1994;155:1393-1403.
35. 35. Aruga A, Aruga E, Tanigawa K, Bishop DK, Sondak VK, Chang AE. Type 1 vs type 2 cytokine release by VB T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol 1997;159:664-670.
36. 36. Hu H-M. Urba WJ, Fox BA. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol 1998;161:3033-3041.
37. 37. Limmer A, et al. Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment. Eur J Immunol 1998:28:2395-2406.
38. + T lymphocytes but fail to promote survival. Eur J Immunol 1998;28:221-236.
39. 39. Crispe IN, Mehal WZ. Strange brew: T cells in the liver. Immunol Today 1996;17:522-525.
40. 40. Ganss R, Hanahan D. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res 1998;58:4673-4681.
41. 41. Allison J, et al. The threshold for autoimmune T cell killing is influenced by B7-1. Eur J Immunol 1998;28:949-960.
42. 42. Girard J-P, Springer TA. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today 1995;16:449-457.
43. 43. Yang X-D, Karin N, Tisch R, Steinman L, McDevitt HO. Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen-4 adhesion receptors. Proc Natl Acad Sci USA 1993;90:10494-10498.
44. 44. Moriyama H, et al. Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway. J Immunol 1996;157:3737-3743.
45. 45. André I, Gonzalez A, Wang B, Katz J, Benoist C, Mathis D. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci USA 1996;93:2260-2263.
46. 46. Austrup F, et al. P-and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues. Nature 1997;385:81-83.
47. 47. Heckmann M, Douwes K, Peter R, Degitz K. Vascular activation of adhesion molecule mRNA and cell surface expression by ionizing radiation. Exp Cell Res 1998;238:148-154.
48. 48. Hallahan D, Kuchibhotla J, Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res 1996;56:5150-5155.
49. 49. Krull M. Nöst R, Hippenstiel S. Domann E, Chakraborty T, Suttrop N. Listeria monocytogenes potently induces up-regulation of endothelial adhesion molecules and neutrophil adhesion to cultured human endothelial cells. J Immunol 1997;159:1970-1976.
50. 50. Unanue ER. Studies in listeriosis show the strong symbiosis between the innate cellular system and the T cell response. Immunol Rev 1997;158:11-25.
51. 51. Brabb T, Goldrath AW, von Dassow P, Paez A, Liggitt HD, Goverman J. Triggers of autoimmune disease in a murine TCR-transgenic model for multiple sclerosis. J Immunol 1997;159:497-507.
52. 52. Greenherg DP. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281-355.
53. 53. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988;48:7022-7032.
54. 54. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
55. 55. Weidner N, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1994;84:1875-1887.
56. 56. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996;2:992-997.
57. 57. Wu NZ, Klitzman B, Dodge R, Dewhirst MW. Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res 1992:52:4265-4268.
58. 58. Weber LW, et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998;102:1258-1264.
59. 59. Nestle FO, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
60. 60. Mitzoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-1798.
61. + T cells specific for a monoclonal immmunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 1996;26:2671-2679.
62. 62. Zeytun A, Hassuneh M, Nagarkatti M, Nagarkatti PS. Fas-FasLigand-based interactions between tumor tells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. Blood 1997;90:1952-1959.